The Biggest Unsolved Problem in Medicine?

Today, over half a billion people battle osteoarthritis. Each year, they spend $240B trying to halt the destruction of joint cartilage. But no cure exists on the market.

Not for lack of trying, either. Big Pharma’s spent billions failing. Thankfully, Cytonics may have cracked the code. 

They discovered the body already produces a cartilage-protecting protein, but not enough and not where it's needed most. So they harnessed it, creating a therapy that has already begun treating the root cause of osteoarthritis in 10,000+ patients. Now they're pushing a 200% more potent, mass-producible version toward FDA approval.

But that's only scratching the surface of why 7,000+ investors have already backed Cytonics.

• Breakthrough: If approved, it could be the first therapy in history to actually halt cartilage destruction and promote regrowth, finally delivering what 500M+ patients have been waiting for.
• Traction: $32M of capital raised to date, including a seven-figure from pro athletes Rener and Eve Gracie, backed by partnerships with Stanford and Scripps Research.
• Opportunity: Everyday investors have the limited-time chance to participate in an early-stage biotech investment opportunity that’s historically been reserved for VCs and institutional investors. 

Claim a piece at the pre-clinical stage as an early-stage Cytonics investor today to be eligible for time-sensitive rewards like up to 15% bonus stock.

This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/